Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-label, 3-period Study to Evaluate Drug-Drug Interaction Potential of Radiprodil With Cocktail Probes Representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP in Healthy Adult Subjects

NCT06975605 is registered in ClinicalTrials.gov with GRIN Therapeutics, Inc. as lead sponsor.

NCT NCT06975605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-label, 3-period Study to Evaluate Drug-Drug Interaction Potential of Radiprodil With Cocktail Probes Representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP in Healthy Adult Subjects
Lead sponsor
GRIN Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 20, 2025
Completion date
July 10, 2025
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focal cortical dysplasia, other neurological disorders, tuberous sclerosis complex (tsc)